Sugi Predict

Sugi Predict / Compounds / SCHEMBL895070

SCHEMBL895070

SCHEMBL895070

CON(C)C(=O)CCCNC(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.53
▸ MEN1 O00255 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ CA1 P00915 8/20 0.44
▸ CA2 P00918 8/20 0.44
▸ CA12 O43570 4/20 0.44
▸ CA9 Q16790 4/20 0.44
▸ CHRM2 P08172 2/20 0.44
▸ CHRM4 P08173 2/20 0.44
▸ CHRM5 P08912 2/20 0.44
▸ CHRM1 P11229 2/20 0.44
▸ CHRM3 P20309 2/20 0.44
▸ EPHX1 P07099 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL500234 0.95 TDP1 (0.55) TDP1MEN1GAAKMT2AMAOA
SCHEMBL3222258 0.94 TDP1 (0.58) TDP1MEN1GAAKMT2AMAOA
SCHEMBL24418335 0.94 TDP1 (0.58) TDP1MEN1GAAKMT2AMAOA
SCHEMBL18688676 0.94 TDP1 (0.58) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2795678 0.90 TDP1 (0.47) TDP1MEN1GAAKMT2AMAOA
SCHEMBL5767251 0.85 TDP1 (0.57) TDP1MEN1GAAKMT2AMAOA
SCHEMBL13036370 0.83 MEN1 (0.43) TDP1MEN1GAAKMT2AMAOA
SCHEMBL12990273 0.81 TDP1 (0.42) TDP1MEN1GAAKMT2AMAOA
SCHEMBL268678 0.80 TDP1 (0.42) TDP1MEN1GAAKMT2AMAOA
SCHEMBL31402165 0.79 TDP1 (0.46) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317777-A1 NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-09-26 — — US disclosed
WO-2024178335-A2 NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS ACCUTAR BIOTECHNOLOGY, INC. (US) 2024-08-29 — — WO disclosed
EP-2560978-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2019-01-30 — — EP disclosed
EP-2560978-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2019-01-30 — — EP disclosed
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2018-09-06 — — US disclosed
US-9994594-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2018-06-12 — — US disclosed
US-9994594-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2018-06-12 — — US disclosed
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2017-06-29 — — US disclosed
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2017-06-29 — — US disclosed
US-9040703-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2015-05-26 — — US disclosed
US-20070276017-A1 Thiadiazoline Derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-11-29 — — US disclosed
US-20070191391-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-16 — — US disclosed
US-20070191391-A1 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-16 — — US disclosed
US-20070179123-A1 Methods and compositions for treating diseases associated with pathogenic proteins CHIANG PETER K 2007-08-02 — — US disclosed
US-20070179123-A1 Methods and compositions for treating diseases associated with pathogenic proteins CHIANG PETER K 2007-08-02 — — US disclosed
WO-2007081995-A2 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-19 — — WO disclosed
WO-2007056580-A2 METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH PATHOGENIC PROTEINS PHARMADYN, INC. (US) 2007-05-18 — — WO disclosed
EP-1632484-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-03-08 — — EP disclosed
EP-1397340-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-03-17 — — EP disclosed
WO-2002098850-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-12-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 TDP1 1161/4885MEN1 2806/4885GAA 694/4885
US-20070276017-A1 Thiadiazoline Derivative BRD7, NR3C2, NR5A2 TDP1 3187/4885MEN1 2331/4885GAA 4855/4885
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 TDP1 1161/4885MEN1 2806/4885GAA 694/4885
US-20070179123-A1 Methods and compositions for treating diseases associated with pathogenic proteins PRNP, APP, PSEN1 TDP1 1237/4885MEN1 2475/4885GAA 304/4885
US-20070191391-A1 Urotensin II receptor antagonists UTS2R, PLAUR, BDKRB2 TDP1 3396/4885MEN1 3006/4885GAA 787/4885
US-20240317777-A1 NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK20, CDK3 TDP1 493/4885MEN1 1719/4885GAA 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.